-
Feb 29, 2024, 08:54 AM
by
Full story
-
Feb 29, 2024, 08:54 AM
by
Full story
-
Feb 29, 2024, 08:54 AM
by
Full story
-
Feb 29, 2024, 08:54 AM
by
Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34M financing round.
Full story
-
Feb 29, 2024, 01:00 AM
by
User Not Found
Bio-IT World | Oxford Nanopore and Lonza have teamed up to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA; Parse updates whole transcriptome kit; and more.
Full story
-
Feb 28, 2024, 09:00 AM
by
User Not Found
Bio-IT World | Ginkgo Bioworks announced three acquisitions today: Reverie Labs, Proof Diagnostics, and Patch Biosciences. The acquisitions will expand Ginkgo’s capabilities for large-scale AI foundation models, its library of RNA programmable, non-Cas enzymes, and its machine learning models and downstream assays.
Full story
-
Feb 28, 2024, 07:34 AM
by
Paving the way to advance cancer research and diagnosis with enriched, high-quality DICOM images
Full story
-
Feb 28, 2024, 07:34 AM
by
New Kalderos board members bring broad legal, regulatory, and corporate leadership experience across healthcare, biopharmaceutical, and pharmacy industries.
Full story
-
Feb 28, 2024, 07:34 AM
by
Optibrium has launched Semeta™, a metabolism prediction platform tailored specifically for drug metabolism and pharmacokinetics (DMPK) scientists. Fundamental to improving a drug’s chance of clinical success, Semeta allows the accurate prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery, with superior precision to comparable software.
Full story
-
Feb 28, 2024, 07:34 AM
by
Also, in 2023, Avalon launched Precision Genetic Testing Management (PGTM), the next evolution of its genetic test management solution.
Full story
-
Feb 28, 2024, 07:34 AM
by
Full story
-
Feb 28, 2024, 07:34 AM
by
Discovery Park, Kent’s thriving life science community, is marking International Women’s Day by supporting women in business and tackling gender bias in healthcare.
Full story
-
Feb 28, 2024, 07:34 AM
by
Full story
-
Feb 28, 2024, 07:34 AM
by
The healthcare industry is embracing automation and robotics, offering exciting changes. Automation empowers healthcare providers by streamlining tasks and allowing for personalized medicine.
Full story
-
Feb 28, 2024, 07:34 AM
by
Full story
-
Feb 28, 2024, 01:00 AM
by
User Not Found
Bio-IT World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer plans to advance its journey toward becoming the foremost provider of self-sampling solutions with new funding, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products; COUR will advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including Phase 2a proof-of-concept clinical studies in Myasthenia Gravis and Type 1 Diabetes, and other pipeline opportunities; and more.
Full story
-
Feb 27, 2024, 08:42 AM
by
Pelago Biosciences has announced that the University of Edinburgh has acknowledged its Cellular Thermal Shift Assay (CETSA®) patent and use thereof in selected works in drug discovery research.
Full story
-
Feb 27, 2024, 08:42 AM
by
Full story
-
Feb 27, 2024, 08:42 AM
by
Full story
-
Feb 27, 2024, 08:42 AM
by
In recent years, the demand for dietary supplements has been on the rise as more and more individuals seek to maintain a healthy lifestyle. Alfa Chemistry, a renowned chemical supplier, has unveiled its selection of dietary supplements, offering consumers a wide range of options to support their nutritional needs. With its new product line, including Fruit Juice Powder, Enzyme Powder, and Probiotics Product, Alfa Chemistry aims to provide natural and effective solutions for various health concerns.
Full story